Short Interest in Adlai Nortye Ltd. (NASDAQ:ANL) Increases By 112.5%

Adlai Nortye Ltd. (NASDAQ:ANL) was the target of a large growth in short interest in the month of December. As of December 31st, there was short interest totalling 6,800 shares, a growth of 112.5% from the December 15th total of 3,200 shares. Based on an average trading volume of 16,400 shares, the days-to-cover ratio is presently 0.4 days.

Wall Street Analyst Weigh In

Separately, HC Wainwright reissued a “buy” rating and set a $9.00 price objective on shares of Adlai Nortye in a report on Monday, November 11th.

Adlai Nortye Trading Up 1.0 %

Shares of ANL opened at $2.03 on Thursday. The stock has a 50-day moving average price of $2.39 and a 200-day moving average price of $2.57. Adlai Nortye has a 12-month low of $1.85 and a 12-month high of $17.48.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.